公开(公告)号：US20150175544A1

公开(公告)日：2015-06-25

申请号：US14415875

申请日：2013-08-05

Applicant: BASF SE

Inventor： Andreas Hafner ,  Fritz Blatter ,  Eva Roedel ,  Martin Szelagiewicz ,  Tiziana Chiodo ,  Tobias Hintermann ,  Beate Salvador ,  Marcus Vossen

IPC: C07D213/81 ,  C07D249/08

CPC classification number: C07D213/81 ,  C07B2200/13 ,  C07D249/08

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.

Abstract translation: 本发明涉及包含式（1）化合物（4- [3,5-双（2-羟基苯基）-1H-1,2,4-三唑-1-基）的多组分结晶体（共晶体） ]苯甲酸; INN：Deferasirox）式（1）和式（2）化合物（异烟酰胺;吡啶-4-甲酰胺）式（2），以及其获得方法。

公开(公告)号：US09221789B2

公开(公告)日：2015-12-29

申请号：US14406264

申请日：2013-06-18

Applicant: BASF SE

Inventor： Tiziana Chiodo ,  Rolf Hellmann ,  Marcus Vossen ,  Beate Salvador ,  Andreas Hafner ,  Tobias Hintermann

IPC: A61K31/506 ,  C07D401/04 ,  C07C55/10 ,  C07C57/15 ,  C07C63/06

CPC classification number: C07D401/04 ,  C07B2200/13 ,  C07C55/10 ,  C07C57/15 ,  C07C63/06

Abstract: Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.

Abstract translation: 包含作为活性成分的4 - [（4-甲基-1-哌嗪基）甲基] -N- [4-甲基-3 - [[4-（3-吡啶基）-2-嘧啶基]氨基] - 苯基] - 苯甲酰胺甲磺酸盐和共结晶前体苯甲酸，富马酸或琥珀酸。 所述多组分结晶形式相对于先前已知的活性药物成分的结晶形式具有改善的物理和生物学性质。

公开(公告)号：US20150133463A1

公开(公告)日：2015-05-14

申请号：US14406339

申请日：2013-06-13

Applicant: BASF SE

Inventor： Tiziana Chiodo ,  Andreas Hafner ,  Tobias Hintermann ,  Beate Salvador ,  Martin Szelagiewicz ,  Fritz Blatter ,  Bernd Siebenhaar ,  Marcus Vossen

IPC: C07D417/12 ,  C07D213/82 ,  A61K31/506 ,  C07C47/58 ,  C07C35/12 ,  C07C65/03 ,  C07D309/40

CPC classification number: C07D417/12 ,  A61K31/506 ,  C07B2200/07 ,  C07B2200/13 ,  C07C35/12 ,  C07C47/58 ,  C07C65/03 ,  C07C69/84 ,  C07D213/82 ,  C07D309/40 ,  A61K2300/00

Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(−)-menthol.

Abstract translation: 提供多组分结晶体（共晶体）及其用途，以及获得该组合物的方法。 所述多组分结晶体（共晶体）包含达沙替尼和选自甲基 - 羟基苯甲酸甲酯，烟酰胺，没食子酸乙酯，没食子酸甲酯，没食子酸丙酯，乙基麦芽酚，香草醛，薄荷醇或（1R，2S，5R） - （ - ） - 薄荷脑

公开(公告)号：US20150126520A1

公开(公告)日：2015-05-07

申请号：US14406264

申请日：2013-06-18

Applicant: BASF SE

Inventor： Tiziana Chiodo ,  Rolf Hellmann ,  Marcus Vossen ,  Beate Salvador ,  Andreas Hafner ,  Tobias Hintermann

IPC: C07D401/04 ,  C07C55/10 ,  C07C57/15 ,  C07C63/06

CPC classification number: C07D401/04 ,  C07B2200/13 ,  C07C55/10 ,  C07C57/15 ,  C07C63/06

Abstract: Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.

Abstract translation: 包含作为活性成分的4 - [（4-甲基-1-哌嗪基）甲基] -N- [4-甲基-3 - [[4-（3-吡啶基）-2-嘧啶基]氨基] - 苯基] - 苯甲酰胺甲磺酸盐和共结晶前体苯甲酸，富马酸或琥珀酸。 所述多组分结晶形式相对于先前已知的活性药物成分的结晶形式具有改善的物理和生物学性质。